Climb Bio Reports Second Quarter 2026 Financial Results and Provides Business Updates
Climb Bio reported $239.2 million in cash and marketable securities as of June 30, 2026, extending its expected runway into the second half of 2028. The company anticipates initiating dosing in the Phase 2 trial of CLYM116 for IgA nephropathy in Q3 2026, with initial Phase 1 data to be presented at an R&D Spotlight event on September 3.
Key figures
- Ga expense
- 5645000
- Rd expense
- 9714000
- Cash runway
- Second half of 2028
- Cash position
- 239200000
- Financing proceeds
- 110000000
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.